Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond
Misako Nagasaka, Bindu Potugari, Alexis Nguyen, et al.
Cancer Treatment Reviews (2021) Vol. 101, pp. 102309-102309
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
E O'Sullivan, Anna Keogh, Brian E. Henderson, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1635-1635
Open Access | Times Cited: 45
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Sahar F. Bannoura, Husain Yar Khan, Asfar S. Azmi
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 61
KRAS in NSCLC: State of the Art and Future Perspectives
Priscilla Cascetta, Arianna Marinello, Chiara Lazzari, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5430-5430
Open Access | Times Cited: 43
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review
Mariacarmela Santarpía, Giuliana Ciappina, Calogera Claudia Spagnolo, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 2, pp. 346-368
Open Access | Times Cited: 29
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
Zining Zhang, Heng Zhang, Xiang Liao, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 28
KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration
Yunkai Yang, Huan Zhang, Shanshan Huang, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 2, pp. 709-709
Open Access | Times Cited: 27
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Firas Batrash, Mahmoud Kutmah, Jun Zhang
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 22
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 10
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Wen‐Jing Xiao, Wenjie Jiang, Zheng Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer
Irene Yu, Anthony Dakwar, Kazuaki Takabe
Cells (2023) Vol. 12, Iss. 2, pp. 258-258
Open Access | Times Cited: 21
RAS degraders: The new frontier for RAS-driven cancers
Taylor E. Escher, K.J.F. Satchell
Molecular Therapy (2023) Vol. 31, Iss. 7, pp. 1904-1919
Open Access | Times Cited: 19
An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2+/PTBP1+ pan-adenocarcinoma
Zunyong Feng, Xuanbo Zhang, Jing Zhou, et al.
Nature Cancer (2023) Vol. 5, Iss. 1, pp. 30-46
Closed Access | Times Cited: 17
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine
Kai‐Bo Wang, Yushuang Liu, Jinzhu Li, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 27
Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
Thomas Yul Avery, Natalie Köhler, Robert Zeiser, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 24
The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
Reese Jalal Ladak, Alexander J. He, Yu-Hsun Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 23
Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles
Alberto Juan, María del Mar Noblejas‐López, María Arenas-Moreira, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 22
Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery
Prasanna Srinivasan Ramalingam, Purushothaman Balakrishnan, Senthilnathan Rajendran, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 3, pp. 2136-2156
Open Access | Times Cited: 14
Advances in the treatment of KRASG12C mutant non–small cell lung cancer
Khvaramze Shaverdashvili, Timothy F. Burns
Cancer (2025) Vol. 131, Iss. S1
Open Access
Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway
Katherine Priest, Anh T. Le, Amanuail Gebregzabheir, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 11
Reverse vaccinology and immunoinformatics approaches to design multi-epitope based vaccine against oncogenic KRAS
Prasanna Srinivasan Ramalingam, Sivakumar Arumugam
Medical Oncology (2023) Vol. 40, Iss. 10
Open Access | Times Cited: 11
Targeting GRP78 suppresses oncogenic KRAS protein expression and reduces viability of cancer cells bearing various KRAS mutations
Dat P. Ha, Bo Huang, Han Wang, et al.
Neoplasia (2022) Vol. 33, pp. 100837-100837
Open Access | Times Cited: 18
Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Maxime Rémond, Anna Pellat, Catherine Brézault, et al.
ESMO Open (2022) Vol. 7, Iss. 6, pp. 100638-100638
Open Access | Times Cited: 17
Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway
Xuenan Hou, Chishun Zhou, Zuhui Liang, et al.
Phytomedicine (2023) Vol. 121, pp. 155093-155093
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top